In honor of the 25th anniversary of The Motley Fool we are talking about oil and gas 25 years ago, the present state of the industry, and our predictions for the future. Thanks to Blooom for supporting Industry Focus.  

Get a month free with blooom401k.com/fool and code FOOL.

A $3 billion project to sequence the human genome in the 90's is at the root of a revolution in patient treatment today. Also, can technology bridge the growing gap between healthcare supply and demand? Stocks: TDOC, ISRG, ILMN

A $3 billion project to sequence the human genome in the 90's is at the root of a revolution in patient treatment today. Also, can technology bridge the growing gap between healthcare supply and demand? Stocks: TDOC, ISRG, ILMN

Our theme week continues as we celebrate the 25th anniversary of The Motley Fool with a look at the innovation and change that could shape the consumer and retail sector going forward.

Thanks to Blooom for supporting Industry Focus. Get a month free with blooom401k.com/fool and code “fool”.

Big news sent Foundation Medicine and Sarepta Therapeutics soaring this week. Meanwhile, PTC Therapeutics investors endured a roller coaster ride. Stocks: FMI, SRPT, PTCT 

Celgene's been stumbling lately, but it's got irons in the fire that could get it back on track. Are this company's best days behind it, or are they only beginning? Stocks: CELG

Our theme week continues as we celebrate the 25th anniversary of The Motley Fool with a look at the innovation and change that could shape the consumer and retail sector going forward.

Thanks to Blooom for supporting Industry Focus. Get a month free with blooom401k.com/fool and code “fool”.

Here’s what has changed in banking over the past 25 years and what we think is in store for the next 25.

Here’s what has changed in banking over the past 25 years and what we think is in store for the next 25.

Data analytics company Domo has plans to go public, but should investors want a piece of this former unicorn?